| HOME >> BIOLOGY >> TECHNOLOGY |
Honorees for best pharmaceutical agent and best biotechnology product to be recognized at Sept. 24 gala ceremony
NEW YORK, Aug. 12 /PRNewswire-USNewswire/ -- The Prix Galien USA 2008 (http://www.prix-galien-usa.com) will recognize innovative biopharmaceutical drugs and devices that have made a deep impact on the quality of human life in ways that range from providing treatment for cancer and HIV/AIDS to hypertension and chronic pain. Charlie Rose will again emcee the awards ceremony on September 24, 2008, to be held at the American Museum of Natural History in New York.
The final candidates for the Prix Galien USA 2008 awards are:
-- Actelion Ltd. - Ventavis(R) (Iloprost)
-- Alexion Pharmaceuticals - Soliris(TM)
-- BioMarin Pharmaceutical Inc. - Nagalzyme(R)
-- Bristol-Myers Squibb - Sprycel(R)
-- Boehringer Ingelheim - Aptivus(R) and Spiriva(R)
-- Celgene Corporation - Revlimid(R)
-- CV Therapeutics Inc. - Ranexa(R) (ranolazine)
-- Elan Corporation - Prialt(R) (ziconotide intrathecal infusion)
-- Eli Lilly Company - Evista(R) raloxifene HCI
-- Genzyme Corporation - Myozyme(R)
-- GlaxoSmithKline - Tykerb(TM) (lapatinib) and Altabax(TM) (retapamulin ointment)
-- Merck & Co. - Isentress(R) (raltegravir)
-- Novartis AG - Exjade(R) (deferasirox) and Tekturna(R)
-- Nycomed - Omnaris
-- Pfizer Inc. - Selzentry(TM)
-- Roche Laboratories Inc. - Boniva(R)
-- sanofi-aventis - Lovenox(R)
-- Sanofi Pasteur - H5N1 influenza virus vaccine
-- Sucampo Pharmaceuticals, Inc. - Amitiza(R)
-- Wyeth - Infuse/InductOs (rh BMP-2 dibotermin alfa) Torisel (temsirolimus) Injection.
"Nominees for the Prix Galien USA stand apart from other drugs in the
marketplace for the amount of research and level of skill that was invested
to develop these innovative medicines that i
'/>"/>
| SOURCE Prix Galien USA Copyright©2008 PR Newswire. All rights reserved |